Abstract 1049
Background
This study is a pretest-posttest, randomized, controlled experimental study that was intended to analyze the effect of multiple initiatives on beliefs about cervical cancer, health responsibility, and screening participation.
Methods
The group that was addressed were women between 40 and 55 years of age who were at risk of cervical cancer. The study was carried out between March 13 and June 18, 2017 in a primary health care center. The sample for this study included 134 women (experimental group: 64; control group; 67). The 14 weeks of sessions involving the experimental group included group training and delivery of brochures on cervical cancer, training and counseling during home visits, reminder phone calls, and delivery of materials, all aimed to increase motivation to be screened regularly for cervical cancer. The control group maintained their routine practices. To prevent any ethical violations, the group training as well as the brochures, magnets, and mugs that were given to the experimental group before the sessions were provided after the post-tests to the control group as well. The study data were collected using an information form, the Cervical Cancer and Pap-Smear Test Health Belief Model Scale, the Healthy Lifestyle Behaviors Scale II (Health Responsibility), and The Assessment Form for Undergoing Pap-Smear Test. The data were analyzed using dependent groups t test and independent groups t test.
Results
After the multiple interventions, there was a significant difference between the test and control groups’ Health Responsibility, Pap smear benefit and motivation, Pap smear obstacle and health motivation scores (p < 0.05). After multiple interventions, the participation rate of women in the experimental group to cervical cancer screening was found to be 93% and the rate of cervical cancer screening was significantly higher than in the control group (p < 0.05).
Conclusions
In the light of the results of these studies, it may be suggested to conduct studies in factorial design where the effectiveness of different methods to increase participation in cervical cancer screening is evaluated.
Clinical trial identification
NCT03076879, 26 September 2017.
Editorial acknowledgement
Legal entity responsible for the study
Busra Altinel.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract
5472 - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Camilla Qvortrup
Session: Poster Display session 2
Resources:
Abstract